A clinical trial is underway to test whether cancer patients can be protected from COVID-19 by daily use of a medicated nasal spray.
The C-SMART trial is now open to anyone with a current or past cancer diagnosis.
The nasal spray used in the trial includes the drug interferon, which disrupts a virus’ ability to replicate.
Professor Monica Slavin, Director of Infectious Diseases at Peter Mac, says cancer patients were still encouraged to be fully vaccinated against COVID-19.
"We are seeing this spray as being a potential additional precaution people can take, as well as being vaccinated," says Prof Slavin, who is also Director of the National Centre for Infections in Cancer.
Read more and register your interest here: www.csmart.com.au